Zealand Pharma Dirección

Dirección controles de criterios 3/4

El CEO de Zealand Pharma's es Adam Steensberg , nombrado en Mar 2022, tiene una permanencia de 2.08 años. compensación anual total es DKK24.84M, compuesta por 23.2% salario y 76.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.069% de las acciones de la empresa, por valor de €3.35M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 9 años, respectivamente.

Información clave

Adam Steensberg

Chief Executive Officer (CEO)

kr.24.8m

Compensación total

Porcentaje del salario del CEO	23.2%
Permanencia del CEO	2.2yrs
Participación del CEO	0.07%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	9.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Adam Steensberg en comparación con los beneficios de Zealand Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	kr.25m	kr.6m	-kr.704m
Sep 30 2023	n/a	n/a	-kr.760m
Jun 30 2023	n/a	n/a	-kr.986m
Mar 31 2023	n/a	n/a	-kr.1b
Dec 31 2022	kr.19m	kr.4m	-kr.966m
Sep 30 2022	n/a	n/a	-kr.855m
Jun 30 2022	n/a	n/a	-kr.845m
Mar 31 2022	n/a	n/a	-kr.608m
Dec 31 2021	kr.10m	kr.3m	-kr.755m
Sep 30 2021	n/a	n/a	-kr.925m
Jun 30 2021	n/a	n/a	-kr.1b
Mar 31 2021	n/a	n/a	-kr.909m
Dec 31 2020	kr.7m	kr.3m	-kr.669m
Sep 30 2020	n/a	n/a	-kr.660m
Jun 30 2020	n/a	n/a	-kr.545m
Mar 31 2020	n/a	n/a	-kr.624m
Dec 31 2019	kr.7m	kr.3m	-kr.572m

Compensación vs. Mercado: La compensación total ($USD3.57M) de Adam está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD3.35M).

Compensación vs. Ingresos: La compensación de Adam ha aumentado mientras la empresa no es rentable.

CEO

Adam Steensberg (49 yo)

2.2yrs

Permanencia

kr.24,837,000

Compensación

Mr. Adam Sinding Steensberg, M.D., serves as President and Chief Executive Officer at Zealand Pharma A/S since March 30, 2022. He had been an Executive Vice President of Research & Development and Chief Me...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Adam Steensberg	President & CEO	2.2yrs	kr.24.84m	0.069% DKK 3.8m
Henriette Wennicke	EVP & CFO	1.5yrs	kr.9.24m	0.0055% DKK 302.5k
Ivan Moller	Executive VP & COO	6.2yrs	sin datos	0.073% DKK 4.0m
David Kendall	Chief Medical Officer and Head of R&D	no data	sin datos	0.015% DKK 819.6k
Mads Kronborg	Head of Investor Relations & Communication	3.8yrs	sin datos	sin datos
Ravinder Chahil	EVP & General Counsel	2.3yrs	sin datos	0.012% DKK 646.1k
Christina Bredal	Executive VP & Chief People Officer	3.1yrs	sin datos	0.011% DKK 593.4k
Jens Mikkelsen	Head of Molecular Pharmacology	no data	sin datos	sin datos
Danilo Verge	Head of Global Medical Affairs	3.7yrs	sin datos	sin datos
Lykke Romer	VP & Head of Finance and Accounting	no data	sin datos	sin datos
Miriam Katz	Assistant Secretary	no data	sin datos	sin datos
Anna Krassowska	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos

3.1yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 22Z se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Leonard Kruimer	Independent Director	5.1yrs	kr.764.00k	0.025% DKK 1.3m
Alf Gunnar Nicklasson	Independent Chairman of the Board	9.1yrs	kr.1.07m	0.030% DKK 1.6m
Kirsten Drejer	Independent Vice Chairman	6.1yrs	kr.583.00k	0.014% DKK 775.7k
Ake Lernmark	Member of Advisory Board	12.5yrs	sin datos	sin datos
Gudmund Korsgard	Board Observer	no data	sin datos	sin datos
Jeffrey Berkowitz	Independent Director	5.1yrs	kr.583.00k	0.013% DKK 723.0k
Bernard Charbonnel	Member of Advisory Board	12.5yrs	sin datos	sin datos
Richard Pratley	Member of Advisory Board	12.5yrs	sin datos	sin datos
Paul Dorian	Member of Advisory Board	12.5yrs	sin datos	sin datos
Gert Van Assche	Member of Advisory Board	12.5yrs	sin datos	sin datos
Bernadette Connaughton	Independent Director	5.1yrs	kr.583.00k	0.014% DKK 749.3k
Anneline Nansen	Employee Representative Director	2.7yrs	kr.281.00k	0.0024% DKK 132.3k

9.1yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 22Z se considera experimentada (9 años de antigüedad promedio).

Zealand Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Recent updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings released: kr.4.19 loss per share (vs kr.5.77 loss in 1Q 2021)

Insufficient new directors

Zealand Pharma Announces CEO Changes

Full year 2021 earnings: Revenues in line with analyst expectations

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

First quarter 2021 earnings released: kr.5.78 loss per share (vs kr.4.98 loss in 1Q 2020)

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Full year 2020 earnings released: kr.22.07 loss per share (vs kr.16.91 loss in FY 2019)

Revenue misses expectations

New 90-day low: €25.56

New 90-day low: €27.18

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Revenue misses expectations

Third quarter 2020 earnings released: kr.5.76 loss per share

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

New 90-day high: €33.36

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

New 90-day low - €29.52

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad